Kraguljac-Kurtović, Nada

Link to this page

Authority KeyName Variants
3cb65d6f-7da8-4c6c-b8bb-8348019aa463
  • Kraguljac-Kurtović, Nada (3)
  • Kraguljac Kurtović, Nada (2)
Projects

Author's Bibliography

Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia

Marjanović, Irena; Kraguljac Kurtović, Nada; Karan-Đurašević, Teodora; Pavlović, Sonja; Tošić, Nataša

(Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade, 2023)

TY  - CONF
AU  - Marjanović, Irena
AU  - Kraguljac Kurtović, Nada
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Tošić, Nataša
PY  - 2023
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/2117
AB  - Introduction: CEBPA gene encodes a transciptional factor with an essential role in granulocyte differentiation process. In acute myeloid leukemia (AML), mutationsin CEBPA gene have been associated with
favorable outcome and up to now only the presence of double mutated CEBPA gene (CEBPAdm) was included in WHO classification. Prognostic influence of CEBPA mutationsin C-terminal (bZIP) region recently
have been proposed as a marker for better overalsurvival (OS), higher probability of achieving complete
remission (CR) and a lower risk of relapse. Since AML with normal karyotype (AML-NK) is a group with intermediate prognosis with the need for new prognostic markers, we analyzed the influence of bZIP CEBPA
mutations as an additional molecular marker in Serbian AML-NK patients.
Methods: CEBPA mutational screening was performed using a multiplex polymerase chain reaction–
based fragment length analysis. A total of 61 bone marrow samples were collected from de novo AMLNK patients.
Results: In our analysis, frequency of CEBPA mutations in Serbian AML-NK patients was 15% (12/61 patients). Six out of 12 patients had mutation in bZIP region (CEBPAbZIP+). All six CEBPAbZIP+ patients (100%)
achieved CR after induction chemotherapy versus 62% of CEBPAbZIP- patients. CEBPAbZIP+ patients showed a significantly longer OS (CEBPAbZIP+ 31.5 months vs CEBPAbZIP- 10 months) and disease free survival
(DFS) (CEBPAbZIP+ 30 months vs CEBPAbZIP- 10.5 months).
Conclusion: Our analysis of Serbian AML-NK patients showed CEBPAdm was not associated with better
prognosis but our results indicate that CEBPAbZIP+ status is a good candidate for a prognostic molecular
marker.
PB  - Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade
C3  - CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
T1  - Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia
EP  - 58
SP  - 58
UR  - https://hdl.handle.net/21.15107/rcub_imagine_2117
ER  - 
@conference{
author = "Marjanović, Irena and Kraguljac Kurtović, Nada and Karan-Đurašević, Teodora and Pavlović, Sonja and Tošić, Nataša",
year = "2023",
abstract = "Introduction: CEBPA gene encodes a transciptional factor with an essential role in granulocyte differentiation process. In acute myeloid leukemia (AML), mutationsin CEBPA gene have been associated with
favorable outcome and up to now only the presence of double mutated CEBPA gene (CEBPAdm) was included in WHO classification. Prognostic influence of CEBPA mutationsin C-terminal (bZIP) region recently
have been proposed as a marker for better overalsurvival (OS), higher probability of achieving complete
remission (CR) and a lower risk of relapse. Since AML with normal karyotype (AML-NK) is a group with intermediate prognosis with the need for new prognostic markers, we analyzed the influence of bZIP CEBPA
mutations as an additional molecular marker in Serbian AML-NK patients.
Methods: CEBPA mutational screening was performed using a multiplex polymerase chain reaction–
based fragment length analysis. A total of 61 bone marrow samples were collected from de novo AMLNK patients.
Results: In our analysis, frequency of CEBPA mutations in Serbian AML-NK patients was 15% (12/61 patients). Six out of 12 patients had mutation in bZIP region (CEBPAbZIP+). All six CEBPAbZIP+ patients (100%)
achieved CR after induction chemotherapy versus 62% of CEBPAbZIP- patients. CEBPAbZIP+ patients showed a significantly longer OS (CEBPAbZIP+ 31.5 months vs CEBPAbZIP- 10 months) and disease free survival
(DFS) (CEBPAbZIP+ 30 months vs CEBPAbZIP- 10.5 months).
Conclusion: Our analysis of Serbian AML-NK patients showed CEBPAdm was not associated with better
prognosis but our results indicate that CEBPAbZIP+ status is a good candidate for a prognostic molecular
marker.",
publisher = "Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade",
journal = "CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia",
title = "Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia",
pages = "58-58",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2117"
}
Marjanović, I., Kraguljac Kurtović, N., Karan-Đurašević, T., Pavlović, S.,& Tošić, N.. (2023). Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia
Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade., 58-58.
https://hdl.handle.net/21.15107/rcub_imagine_2117
Marjanović I, Kraguljac Kurtović N, Karan-Đurašević T, Pavlović S, Tošić N. Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia. in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia. 2023;:58-58.
https://hdl.handle.net/21.15107/rcub_imagine_2117 .
Marjanović, Irena, Kraguljac Kurtović, Nada, Karan-Đurašević, Teodora, Pavlović, Sonja, Tošić, Nataša, "Prognostic significance of cebpa mutations in patients with normal-karyotype - acute myeloid leukemia" in CoMBoS2 – the Second Congress of Molecular Biologists of Serbia, Abstract Book – Trends in Molecular Biology, Special issue 06-08 October 2023, Belgrade, Serbia (2023):58-58,
https://hdl.handle.net/21.15107/rcub_imagine_2117 .

De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript)

Jaković, Ljubomir; Fekete, Marija Dencic; Virijević, Marijana; Kraguljac Kurtović, Nada; Todorić-Zivanović, Biljana; Stamatović, Dragana; Karan-Đurašević, Teodora; Pavlović, Sonja; Leković, Danijela; Bogdanović, Andrija

(Heidelberg : Springer, 2022)

TY  - JOUR
AU  - Jaković, Ljubomir
AU  - Fekete, Marija Dencic
AU  - Virijević, Marijana
AU  - Kraguljac Kurtović, Nada
AU  - Todorić-Zivanović, Biljana
AU  - Stamatović, Dragana
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Leković, Danijela
AU  - Bogdanović, Andrija
PY  - 2022
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1592
AB  - De novo AMLs with typical nonrandom chromosomal abnormalities are often associated with specific morphology subtypes. The t(8;21) is one of the most prominent recurrent cytogenetic aberrations (RCA) in AML, frequently associated with AML with maturation, and is characterized as a good prognostic marker. On the contrary, BCR::ABL1 rearrangement is rarely observed in AMLs, without specific morphology, carrying poor prognosis. Its distinction from blastic transformation of chronic myeloid leukemia has been a matter of long debate. The revised WHO classification (2016) recognized AML with BCR::ABL1(+) as a provisional entity. The occurrence of additional cytogenetic aberrations in AML RCA within the same leukemic clone has been detected, albeit rare cases of BCR::ABL1(+) were reported, mainly as subclones. Those additional cytogenetic and molecular findings seem to significantly affect patient prognosis. Conventional cytogenetic analysis, fluorescent in situ hybridization (FISH), and polymerase chain reaction (PCR) were applied at presentation and during the follow-up of the patient. We present a 34-year-old male patient with de novo AML harboring concomitant t(8;21) and t(9;22) in a single clone. The presence of both t(8;21) and Philadelphia chromosome (Ph+) in the same metaphases but in less than 100% of the analyzed cells, the p190 BCR::ABL transcript type, and absence of splenomegaly support that additional BCR::ABL1(+) is a part of the main leukemic clone. These findings, accompanied with an encouraging outcome of continuous cytogenetic and molecular remission after induction therapy, support BCR::ABL1 being a secondary genetic event in AML with t(8;21).
PB  - Heidelberg : Springer
T2  - Journal of Hematopathology
T1  - De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript)
EP  - 195
IS  - 3
SP  - 191
VL  - 15
DO  - 10.1007/s12308-022-00509-4
ER  - 
@article{
author = "Jaković, Ljubomir and Fekete, Marija Dencic and Virijević, Marijana and Kraguljac Kurtović, Nada and Todorić-Zivanović, Biljana and Stamatović, Dragana and Karan-Đurašević, Teodora and Pavlović, Sonja and Leković, Danijela and Bogdanović, Andrija",
year = "2022",
abstract = "De novo AMLs with typical nonrandom chromosomal abnormalities are often associated with specific morphology subtypes. The t(8;21) is one of the most prominent recurrent cytogenetic aberrations (RCA) in AML, frequently associated with AML with maturation, and is characterized as a good prognostic marker. On the contrary, BCR::ABL1 rearrangement is rarely observed in AMLs, without specific morphology, carrying poor prognosis. Its distinction from blastic transformation of chronic myeloid leukemia has been a matter of long debate. The revised WHO classification (2016) recognized AML with BCR::ABL1(+) as a provisional entity. The occurrence of additional cytogenetic aberrations in AML RCA within the same leukemic clone has been detected, albeit rare cases of BCR::ABL1(+) were reported, mainly as subclones. Those additional cytogenetic and molecular findings seem to significantly affect patient prognosis. Conventional cytogenetic analysis, fluorescent in situ hybridization (FISH), and polymerase chain reaction (PCR) were applied at presentation and during the follow-up of the patient. We present a 34-year-old male patient with de novo AML harboring concomitant t(8;21) and t(9;22) in a single clone. The presence of both t(8;21) and Philadelphia chromosome (Ph+) in the same metaphases but in less than 100% of the analyzed cells, the p190 BCR::ABL transcript type, and absence of splenomegaly support that additional BCR::ABL1(+) is a part of the main leukemic clone. These findings, accompanied with an encouraging outcome of continuous cytogenetic and molecular remission after induction therapy, support BCR::ABL1 being a secondary genetic event in AML with t(8;21).",
publisher = "Heidelberg : Springer",
journal = "Journal of Hematopathology",
title = "De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript)",
pages = "195-191",
number = "3",
volume = "15",
doi = "10.1007/s12308-022-00509-4"
}
Jaković, L., Fekete, M. D., Virijević, M., Kraguljac Kurtović, N., Todorić-Zivanović, B., Stamatović, D., Karan-Đurašević, T., Pavlović, S., Leković, D.,& Bogdanović, A.. (2022). De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript). in Journal of Hematopathology
Heidelberg : Springer., 15(3), 191-195.
https://doi.org/10.1007/s12308-022-00509-4
Jaković L, Fekete MD, Virijević M, Kraguljac Kurtović N, Todorić-Zivanović B, Stamatović D, Karan-Đurašević T, Pavlović S, Leković D, Bogdanović A. De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript). in Journal of Hematopathology. 2022;15(3):191-195.
doi:10.1007/s12308-022-00509-4 .
Jaković, Ljubomir, Fekete, Marija Dencic, Virijević, Marijana, Kraguljac Kurtović, Nada, Todorić-Zivanović, Biljana, Stamatović, Dragana, Karan-Đurašević, Teodora, Pavlović, Sonja, Leković, Danijela, Bogdanović, Andrija, "De novo acute myeloid leukemia harboring concomitant t(8;21)(q22;q22);RUNX1::RUNX1T1 and BCR::ABL1 (p190 minor transcript)" in Journal of Hematopathology, 15, no. 3 (2022):191-195,
https://doi.org/10.1007/s12308-022-00509-4 . .
1
2
1

Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem

Đorđević, Vesna; Tošić, Nataša; Denčić-Fekete, Marija; Virijević, Marijana; Jovanović, Jelica; Jaković, Ljubomir; Kraguljac-Kurtović, Nada; Bogdanović, Andrija; Kostić, Tatjana; Pavlović, Sonja

(Vojnomedicinska akademija - Institut za naučne informacije, Beograd, 2020)

TY  - JOUR
AU  - Đorđević, Vesna
AU  - Tošić, Nataša
AU  - Denčić-Fekete, Marija
AU  - Virijević, Marijana
AU  - Jovanović, Jelica
AU  - Jaković, Ljubomir
AU  - Kraguljac-Kurtović, Nada
AU  - Bogdanović, Andrija
AU  - Kostić, Tatjana
AU  - Pavlović, Sonja
PY  - 2020
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1371
AB  - Uvod. Precizno dijagnostikovanje akutne promijelocitne leukemije (APL), ne samo na osnovu morfoloških i kliničkih parametara, već i na molekularnom nivou, veoma je važno radi primene adekvatne ciljane terapije. Prikaz bolesnika. Prikazali smo bolesnicu, staru 62 godine, sa dijagnozom APL. Primenom standardne citogenetičke analize, kao i primenom fluorescentne in situ hibridizacije (FISH), nije bilo potvrđeno prisustvo t(15;17) kod opisane bolesnice. Primenom metode reverzna transkriptazalančana reakcija polimeraze (RT-PCR), identifikovana su dva atipična promyelotic leukemia/retinoic acid receptor alpha (PML/RAR-α) fuziona transkripta. Oba transkripta su predstavljala izoforme. Duži transkript je zadržao "okvir čitanja" i kodirao je funkcionalan PML/RAR-α aberantni protein, dok je kraći transkript bio van "okvira čitanja". Zaključak. Naša studija ukazuje na potrebu za primenom molekularne metodologije u svakodnevnoj kliničkoj praksi. Precizna karakterizacija PML/RAR-α fuzionih transkipta čini osnovu za identifikovanje retkih bolesnika čije lečenje zahteva dodatni oprez. Prema našim saznanjima, ovo je tek peti slučaj opisanog atipičnog PML/RAR-α transkripta koji u sebi sadrži celokupan PML egzon 7a, a među njima jedini koji se nije mogao detektovati primenom citogenetičke i FISH analize. Svi ovde predstavljeni slučajevi su imali smrtni ishod. Zbog toga, naši rezulatati, zajedno sa sličnim slučajevima opisanim u literaturi, naglašavaju značaj detaljne identifikacije atipičnih PML/RAR-α fuzija, ne samo u svrhu prepoznavanja njihove uloge u procesu leukemogeneze, veći i u smislu procene njihovog uticaja na ishod lečenja.
AB  - Introduction. The accurate diagnosis of acute promyelocytic leukemia (APL), not only on the morphological and clinical, but also on the molecular level, is very important for application of targeted therapies. Case report. A 62year-old woman presented with APL. By using conventional cytogenetic analysis as well as applying the fluorescence in situ hybridization (FISH) analysis it has not been possible to confirm the presence of t(15;17) in the presented patient. Using reverse transcriptase polymerase chain reaction (RT-PCR) two atypical promyelotic leukemia/retinoic acid receptor alpha (PML/RAR-α) fusion transcripts were identified. Both detected transcripts were isoforms. The larger transcript was in-frame, coding for functional aberrant PML/RAR-α protein, while the shorter transcript was an out-of-frame. Conclusion. Our study highlights the need for the application of molecular methodology in daily clinical practice. Precise characterization of PML/RAR-α fusion transcript creates a basis for identifying rare individual cases that require special caution when treating such patients. To our knowledge this is only the fifth case of atypical PML/RAR-α transcript containing full PML exon 7a, and among them the only one that was cytogenetically cryptic and FISH negative. All of the herein presented cases had lethal outcome. Therefore, our findings with the additional review of the literature, emphasizes the importance of detailed identification of atypical PML/RAR-α fusions, not only for the purpose of knowing their role in leukemogenesis, but also for the assessment of the impact that they can have on the outcome of the treatment.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem
T1  - Acute promyelocytic leukemia lacking t(15;17): Molecular evidence of atypical PML/RAR-α transcriptional variant by gene sequencing
EP  - 102
IS  - 1
SP  - 97
VL  - 77
DO  - 10.2298/VSP170620040D
ER  - 
@article{
author = "Đorđević, Vesna and Tošić, Nataša and Denčić-Fekete, Marija and Virijević, Marijana and Jovanović, Jelica and Jaković, Ljubomir and Kraguljac-Kurtović, Nada and Bogdanović, Andrija and Kostić, Tatjana and Pavlović, Sonja",
year = "2020",
abstract = "Uvod. Precizno dijagnostikovanje akutne promijelocitne leukemije (APL), ne samo na osnovu morfoloških i kliničkih parametara, već i na molekularnom nivou, veoma je važno radi primene adekvatne ciljane terapije. Prikaz bolesnika. Prikazali smo bolesnicu, staru 62 godine, sa dijagnozom APL. Primenom standardne citogenetičke analize, kao i primenom fluorescentne in situ hibridizacije (FISH), nije bilo potvrđeno prisustvo t(15;17) kod opisane bolesnice. Primenom metode reverzna transkriptazalančana reakcija polimeraze (RT-PCR), identifikovana su dva atipična promyelotic leukemia/retinoic acid receptor alpha (PML/RAR-α) fuziona transkripta. Oba transkripta su predstavljala izoforme. Duži transkript je zadržao "okvir čitanja" i kodirao je funkcionalan PML/RAR-α aberantni protein, dok je kraći transkript bio van "okvira čitanja". Zaključak. Naša studija ukazuje na potrebu za primenom molekularne metodologije u svakodnevnoj kliničkoj praksi. Precizna karakterizacija PML/RAR-α fuzionih transkipta čini osnovu za identifikovanje retkih bolesnika čije lečenje zahteva dodatni oprez. Prema našim saznanjima, ovo je tek peti slučaj opisanog atipičnog PML/RAR-α transkripta koji u sebi sadrži celokupan PML egzon 7a, a među njima jedini koji se nije mogao detektovati primenom citogenetičke i FISH analize. Svi ovde predstavljeni slučajevi su imali smrtni ishod. Zbog toga, naši rezulatati, zajedno sa sličnim slučajevima opisanim u literaturi, naglašavaju značaj detaljne identifikacije atipičnih PML/RAR-α fuzija, ne samo u svrhu prepoznavanja njihove uloge u procesu leukemogeneze, veći i u smislu procene njihovog uticaja na ishod lečenja., Introduction. The accurate diagnosis of acute promyelocytic leukemia (APL), not only on the morphological and clinical, but also on the molecular level, is very important for application of targeted therapies. Case report. A 62year-old woman presented with APL. By using conventional cytogenetic analysis as well as applying the fluorescence in situ hybridization (FISH) analysis it has not been possible to confirm the presence of t(15;17) in the presented patient. Using reverse transcriptase polymerase chain reaction (RT-PCR) two atypical promyelotic leukemia/retinoic acid receptor alpha (PML/RAR-α) fusion transcripts were identified. Both detected transcripts were isoforms. The larger transcript was in-frame, coding for functional aberrant PML/RAR-α protein, while the shorter transcript was an out-of-frame. Conclusion. Our study highlights the need for the application of molecular methodology in daily clinical practice. Precise characterization of PML/RAR-α fusion transcript creates a basis for identifying rare individual cases that require special caution when treating such patients. To our knowledge this is only the fifth case of atypical PML/RAR-α transcript containing full PML exon 7a, and among them the only one that was cytogenetically cryptic and FISH negative. All of the herein presented cases had lethal outcome. Therefore, our findings with the additional review of the literature, emphasizes the importance of detailed identification of atypical PML/RAR-α fusions, not only for the purpose of knowing their role in leukemogenesis, but also for the assessment of the impact that they can have on the outcome of the treatment.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem, Acute promyelocytic leukemia lacking t(15;17): Molecular evidence of atypical PML/RAR-α transcriptional variant by gene sequencing",
pages = "102-97",
number = "1",
volume = "77",
doi = "10.2298/VSP170620040D"
}
Đorđević, V., Tošić, N., Denčić-Fekete, M., Virijević, M., Jovanović, J., Jaković, L., Kraguljac-Kurtović, N., Bogdanović, A., Kostić, T.,& Pavlović, S.. (2020). Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 77(1), 97-102.
https://doi.org/10.2298/VSP170620040D
Đorđević V, Tošić N, Denčić-Fekete M, Virijević M, Jovanović J, Jaković L, Kraguljac-Kurtović N, Bogdanović A, Kostić T, Pavlović S. Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem. in Vojnosanitetski pregled. 2020;77(1):97-102.
doi:10.2298/VSP170620040D .
Đorđević, Vesna, Tošić, Nataša, Denčić-Fekete, Marija, Virijević, Marijana, Jovanović, Jelica, Jaković, Ljubomir, Kraguljac-Kurtović, Nada, Bogdanović, Andrija, Kostić, Tatjana, Pavlović, Sonja, "Akutna promijelocitna leukemija bez t(15;17) - molekularni dokazi atipične PML/RAR-α transkripcione varijante genskim sekvenciranjem" in Vojnosanitetski pregled, 77, no. 1 (2020):97-102,
https://doi.org/10.2298/VSP170620040D . .
1
1
1

P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association

Fekete, Marija Dencic; Jaković, Ljubomir; Virijević, Marijana; Jovanović, Jelica; Todorić-Zivanović, Biljana; Karan-Đurašević, Teodora; Kraguljac-Kurtović, Nada; Pavlović, Sonja; Bogdanović, Andrija

(BMC, London, 2019)

TY  - CONF
AU  - Fekete, Marija Dencic
AU  - Jaković, Ljubomir
AU  - Virijević, Marijana
AU  - Jovanović, Jelica
AU  - Todorić-Zivanović, Biljana
AU  - Karan-Đurašević, Teodora
AU  - Kraguljac-Kurtović, Nada
AU  - Pavlović, Sonja
AU  - Bogdanović, Andrija
PY  - 2019
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1249
PB  - BMC, London
C3  - Molecular Cytogenetics
T1  - P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association
VL  - 12
UR  - https://hdl.handle.net/21.15107/rcub_imagine_1249
ER  - 
@conference{
author = "Fekete, Marija Dencic and Jaković, Ljubomir and Virijević, Marijana and Jovanović, Jelica and Todorić-Zivanović, Biljana and Karan-Đurašević, Teodora and Kraguljac-Kurtović, Nada and Pavlović, Sonja and Bogdanović, Andrija",
year = "2019",
publisher = "BMC, London",
journal = "Molecular Cytogenetics",
title = "P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association",
volume = "12",
url = "https://hdl.handle.net/21.15107/rcub_imagine_1249"
}
Fekete, M. D., Jaković, L., Virijević, M., Jovanović, J., Todorić-Zivanović, B., Karan-Đurašević, T., Kraguljac-Kurtović, N., Pavlović, S.,& Bogdanović, A.. (2019). P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association. in Molecular Cytogenetics
BMC, London., 12.
https://hdl.handle.net/21.15107/rcub_imagine_1249
Fekete MD, Jaković L, Virijević M, Jovanović J, Todorić-Zivanović B, Karan-Đurašević T, Kraguljac-Kurtović N, Pavlović S, Bogdanović A. P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association. in Molecular Cytogenetics. 2019;12.
https://hdl.handle.net/21.15107/rcub_imagine_1249 .
Fekete, Marija Dencic, Jaković, Ljubomir, Virijević, Marijana, Jovanović, Jelica, Todorić-Zivanović, Biljana, Karan-Đurašević, Teodora, Kraguljac-Kurtović, Nada, Pavlović, Sonja, Bogdanović, Andrija, "P1143-De novo acute myeloid leukemia with BCR ABL1 accompanied by t(8;21)(q22;q22.1) RUNX1 RUNX1T1 a rare association" in Molecular Cytogenetics, 12 (2019),
https://hdl.handle.net/21.15107/rcub_imagine_1249 .

The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities

Jaković, Ljubomir; Bogdanović, Andrija; Đorđević, Vesna; Denčić-Fekete, Marija; Kraguljac-Kurtović, Nada; Knezević, Vesna; Tošić, Nataša; Pavlović, Sonja; Terzić, Tatjana

(Pergamon-Elsevier Science Ltd, Oxford, 2018)

TY  - JOUR
AU  - Jaković, Ljubomir
AU  - Bogdanović, Andrija
AU  - Đorđević, Vesna
AU  - Denčić-Fekete, Marija
AU  - Kraguljac-Kurtović, Nada
AU  - Knezević, Vesna
AU  - Tošić, Nataša
AU  - Pavlović, Sonja
AU  - Terzić, Tatjana
PY  - 2018
UR  - https://imagine.imgge.bg.ac.rs/handle/123456789/1126
AB  - This study explores cytomorphologic features and their predictive role for early identification of acute myeloid leukemia (AML) with morphological distinctive recurrent cytogenetic abnormalities (RCA): t(15;17), t(8;21) and inv(16)/t(16;16). We retrospectively evaluated 396 de novo AML cases, diagnosed and treated at single institution, between 2013-2017. Specific cytomorphologic features suggesting distinctive AML-RCA were revealed at diagnosis in 62 (15.65%) patients, including AML with t(15;17) in 41 (66.13%), t(8;21) in 13 (20.97%) and inv(16)/t(16;16) in 8 (12.90%). Final diagnoses of AML-RCA according to WHO integrated diagnostic criteria were established in 66 (16.66%) cases, including AML with t(15;17) 40 (60.60%), t(8;21) 17 (25.76%), and inv(16)/t(16;16) 9 (13.64%). Discordance between cytomorphological and other integrated criteria was detected as missed/wrong-call in 0/1 for t(15;17), 6/2 for t(8;21) and 2/1 for inv(16)/t(16;16). The cytomorphological accuracy was 97.56% (40/41) for t(15;17), 57.89% (11/19) for t(8;21) and 70% (7/10) for inv (16)/t(16;16). Positive/negative predictive values of cytomorphological evaluation were: 97.56%/100% for t(15;17); 84.62%/88.68% for t(8;21);87.50%/96.65% for inv(16)/t(16;16). Sensitivity/specificity were: 100%/96.15% for t(15;17);64.10%/95.92% for t(8;21);77.78%/98.25% for inv(16)/t(16;16). We confirmed that morphology is still a highly relevant evaluation method in diagnosing several common AML-RCAs before completing cytogenetic and molecular studies, enabling early detection, particularly of AML with t(15;17).
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Leukemia Research
T1  - The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities
EP  - 28
SP  - 23
VL  - 75
DO  - 10.1016/j.leukres.2018.10.017
ER  - 
@article{
author = "Jaković, Ljubomir and Bogdanović, Andrija and Đorđević, Vesna and Denčić-Fekete, Marija and Kraguljac-Kurtović, Nada and Knezević, Vesna and Tošić, Nataša and Pavlović, Sonja and Terzić, Tatjana",
year = "2018",
abstract = "This study explores cytomorphologic features and their predictive role for early identification of acute myeloid leukemia (AML) with morphological distinctive recurrent cytogenetic abnormalities (RCA): t(15;17), t(8;21) and inv(16)/t(16;16). We retrospectively evaluated 396 de novo AML cases, diagnosed and treated at single institution, between 2013-2017. Specific cytomorphologic features suggesting distinctive AML-RCA were revealed at diagnosis in 62 (15.65%) patients, including AML with t(15;17) in 41 (66.13%), t(8;21) in 13 (20.97%) and inv(16)/t(16;16) in 8 (12.90%). Final diagnoses of AML-RCA according to WHO integrated diagnostic criteria were established in 66 (16.66%) cases, including AML with t(15;17) 40 (60.60%), t(8;21) 17 (25.76%), and inv(16)/t(16;16) 9 (13.64%). Discordance between cytomorphological and other integrated criteria was detected as missed/wrong-call in 0/1 for t(15;17), 6/2 for t(8;21) and 2/1 for inv(16)/t(16;16). The cytomorphological accuracy was 97.56% (40/41) for t(15;17), 57.89% (11/19) for t(8;21) and 70% (7/10) for inv (16)/t(16;16). Positive/negative predictive values of cytomorphological evaluation were: 97.56%/100% for t(15;17); 84.62%/88.68% for t(8;21);87.50%/96.65% for inv(16)/t(16;16). Sensitivity/specificity were: 100%/96.15% for t(15;17);64.10%/95.92% for t(8;21);77.78%/98.25% for inv(16)/t(16;16). We confirmed that morphology is still a highly relevant evaluation method in diagnosing several common AML-RCAs before completing cytogenetic and molecular studies, enabling early detection, particularly of AML with t(15;17).",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Leukemia Research",
title = "The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities",
pages = "28-23",
volume = "75",
doi = "10.1016/j.leukres.2018.10.017"
}
Jaković, L., Bogdanović, A., Đorđević, V., Denčić-Fekete, M., Kraguljac-Kurtović, N., Knezević, V., Tošić, N., Pavlović, S.,& Terzić, T.. (2018). The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities. in Leukemia Research
Pergamon-Elsevier Science Ltd, Oxford., 75, 23-28.
https://doi.org/10.1016/j.leukres.2018.10.017
Jaković L, Bogdanović A, Đorđević V, Denčić-Fekete M, Kraguljac-Kurtović N, Knezević V, Tošić N, Pavlović S, Terzić T. The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities. in Leukemia Research. 2018;75:23-28.
doi:10.1016/j.leukres.2018.10.017 .
Jaković, Ljubomir, Bogdanović, Andrija, Đorđević, Vesna, Denčić-Fekete, Marija, Kraguljac-Kurtović, Nada, Knezević, Vesna, Tošić, Nataša, Pavlović, Sonja, Terzić, Tatjana, "The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities" in Leukemia Research, 75 (2018):23-28,
https://doi.org/10.1016/j.leukres.2018.10.017 . .
7
6